monoclonal antibodies

Question 1

IRCRS

Answer 1

infusion related cytokine release syndrome

chills, hypotension, bronchospasm, dyspnoea, angioedema, nausea,vomitting

Question 2

brentuximab vedoitin indication

Answer 2

refractory hodgkin lymphoma
refractory systemic anaplastic large cell lymphoma
cd30 specific chimeric igG1 antibody

Question 3

bevacizumab indication

Answer 3

advancerd crc, breast, non sq nslc, rcc, ovarian

Question 4

bevaci dose limitting

Answer 4

thrombo embolism, TIA angina, MI, git perforation, wound dehiscence

Question 5

bevaci dose

Answer 5

5-10mg/kg 2 kly

15 mg/ lg 3 wkly

Question 6

bevaci interaction with other drugs

Answer 6

irinotecan severe diarrhoea
sorafenib hand foot syndrome
sunitinib microangiopathic hemolytic anemia( avoid this combi)
anthracycline cardiac toxicity increased

Question 7

alk inhibitos

Answer 7

alectinib
ceritinib
crizotinib

Question 8

indication of crizotinib

Answer 8

metastatic or locally advancedalk positive lung cancer

Question 9

how crizotinib acts

Answer 9

inhibit alk anaplastic lymphoma kinase

hepatocyte growth factor receptor

Question 10

bcr abl inhibitirs

Answer 10

bosutinib
dasatinib
imatinib
nilotinib

Question 11

dasatinib indication

Answer 11

chronic accelerated or blast phase of ph chr positive ALL

Question 12

imatinib dose

Answer 12

Imatinib: 400 to 600 mg orally, daily (with food); 400 mg orally, BID (with food) for dermatofibrosarcoma protuberans

Question 13

dasatinib dose

Answer 13

• Dasatinib: 100 to 140 mg orally, daily

Question 14

PARP INHIBITORS

Answer 14

olaparib

Question 15

how olaoarib (lynparza) works

Answer 15

inhibits PARP 1,2,3. PARp are involved in normal cellular homeostasis. such as dna transcription, cell cycle regulation and dna repair

Question 16

indication of olaparib

Answer 16

brca 1, 2 mutated advanced ovarian cancer treated with prior 3 or more lines of chemo